News

Elevated Lp(a) adds to healthcare burden in patients with ASCVD

July 23, 2025

People with elevated Lp(a) levels and previous atherosclerotic cardiovascular disease (ASCVD) use more healthcare resources, with greater costs and higher rates of major adverse cardiovascular events (MACE) than those with ASCVD alone, according to healthcare data from Alberta, Canada.

First trimester Lp(a) and poor pregnancy outcomes

June 20, 2025

Pre-eclampsia (PE), foetal growth restriction, gestational hypertension and premature delivery all appear to be more common in women with raised Lp(a) in the first trimester of pregnancy. In a prospective study of 150 pregnant women at less than 12 weeks of foetal gestation with no history of PE, 64.7% of participants with Lp(a) ≥30 mg/dL […]

Brussels Declaration calls for Lp(a) testing in CV health plans 

May 13, 2025

The Brussels International Declaration on Lp(a) testing and management has been published in Atherosclerosis, as a clear roadmap for policymakers to implement practical, life-changing policies and systemic reforms focused on the importance of Lp(a) as an independent causal risk factor for cardiovascular (CV) disease.

Lp(a) testing is cost effective in high income countries

April 1, 2025

A new cost effectiveness analysis of Lp(a) testing for primary prevention, carried out for the FH Europe Foundation as part of the Lp(a) International Taskforce initiative, has demonstrated the potential for major cost savings across 11 high income countries*, together with reductions in cardiovascular events.

Waist-to-hip ratio modifies Lp(a) risk of ASCVD 

March 14, 2025

Waist-to-hip ratio (WHR) significantly modifies the risk of atherosclerotic cardiovascular disease (ASCVD) associated with Lp(a). This is the finding from an analysis of data from 4652 participants in the Multi-Ethnic Study of Atherosclerosis (MESA). 

OCEAN(a)-DOSE trial shows olpasiran reduces OxPL-apoB 

February 18, 2025

Olpasiran significantly reduces apoB-associated oxidised phospholipids (OxPL-apoB), according to results of a pre-specified analysis of data from the Phase 2 OCEAN(a)-DOSE trial.